Leerink Partnrs Estimates NeuroPace FY2029 Earnings

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for NeuroPace in a note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky forecasts that the company will post earnings per share of $0.43 for the year. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Company lifted their target price on NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday. UBS Group started coverage on NeuroPace in a report on Tuesday, January 21st. They set a "buy" rating and a $17.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their target price on NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.80.

NeuroPace Stock Performance

NASDAQ NPCE traded down $0.35 during midday trading on Thursday, hitting $13.41. The company had a trading volume of 96,500 shares, compared to its average volume of 163,800. The firm has a fifty day simple moving average of $11.84 and a two-hundred day simple moving average of $8.87. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.15. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The stock has a market cap of $400.29 million, a price-to-earnings ratio of -13.45 and a beta of 2.05.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $21.06 million during the quarter, compared to analysts' expectations of $19.33 million. During the same period in the prior year, the business earned ($0.28) earnings per share.

Insider Transactions at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of the firm's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the sale, the insider now owns 87,062 shares in the company, valued at approximately $1,306,800.62. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 22.20% of the stock is currently owned by insiders.

Institutional Trading of NeuroPace

Several hedge funds have recently modified their holdings of NPCE. KCK LTD. bought a new position in NeuroPace in the fourth quarter valued at about $58,981,000. Millennium Management LLC boosted its stake in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company's stock valued at $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Geode Capital Management LLC grew its position in shares of NeuroPace by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock worth $2,211,000 after buying an additional 25,330 shares during the period. State Street Corp raised its stake in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company's stock worth $1,084,000 after buying an additional 12,912 shares during the last quarter. Finally, Financial Advocates Investment Management lifted its holdings in NeuroPace by 27.8% in the fourth quarter. Financial Advocates Investment Management now owns 23,000 shares of the company's stock valued at $257,000 after buying an additional 5,000 shares during the period. 78.83% of the stock is owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.